Skip to Content

Posts tagged with "Drug Development"

  • Business and Markets

    A Federation of Independent Researchers?

    I’ve had an interesting e-mail from a reader who wants to be signed as “Mrs. McGreevy”, and it’s comprehensive enough that I’m going to reproduce it in full below. As everyone but the editorial board of C&E News has noticed, jobs in chemistry are few and far between right now. I found your post on… Read More
  • Drug Assays

    The Artificial Intelligence Economy?

    Now here’s something that might be about to remake the economy, or (on the other robotic hand) it might not be ready to just yet. And it might be able to help us out in drug R&D, or it might turn out to be mostly beside the point. What the heck am I talking about… Read More
  • Drug Development

    Winning Ugly and Failing Gracefully

    A recent discussion with colleagues turned around the question: “Would you rather succeed ugly or fail gracefully?” In drug discovery terms, that could be rephrased “Would you rather get a compound through the clinic after wrestling with a marginal structure, worrying about tox, having to fix the formulation three times, and so on… Read More
  • Business and Markets

    Virtual Biotech, Like It or Not

    We’ve all been hearing for a while about “virtual biotechs”. The term usually refers to a company with only a handful of employees and no real laboratory space of its own. All the work is contracted out. That means that what’s left back at the tiny headquarters (which in a couple of cases is as… Read More
  • Drug Development

    What’s the Ugliest Drug? Or The Ugliest Drug Candidate?

    I was having one of those “drug-like properties” discussions with colleagues the other day. Admittedly, if you’re not in drug discovery yourself, you probably don’t have that one very often, but even for us, you’d think that a lot of the issues would be pretty settled by now. Not so. While everyone broadly agrees that… Read More
  • Drug Assays

    Dealing with the Data

    So how do we deal with the piles of data? A reader sent along this question, and it’s worth thinking about. Drug research – even the preclinical kind – generates an awful lot of information. The other day, it was pointed out that one of our projects, if you expanded everything out, would be displayed… Read More
  • Academia (vs. Industry)

    Merck’s CALIBR Venture

    So the news is that Merck is now going to start its own nonprofit drug research institute in San Diego: CALIBR, the California Institute for Biomedical Research. It’ll be run by Peter Schultz of Scripps, and they’re planning to hire about 150 scientists (which is good news, anyway, since the biomedical employment picture out in… Read More
  • Drug Development

    Not Quite So Accelerated, Says PhRMA

    We’ve spent a lot of time here talking about provisional approval of drugs, most specifically Avastin (when its approval for metastatic breast cancer was pulled). But the idea isn’t to put drugs on the market that have to be taken back; it’s to get them out more quickly in case they actually work. There’s legislation… Read More
  • Drug Assays

    The Blackian Demon of Drug Discovery

    There’s an on-line appendix to that Nature Reviews Drug Discovery article that I’ve been writing about, and I don’t think that many people have read it yet. Jack Scannell, one of the authors, sent along a note about it, and he’s interested to see what the readership here makes of it. It gets to the… Read More
  • Drug Development

    The Brute Force Bias

    I wanted to return to that Nature Reviews Drug Discovery article I blogged about the other day. There’s one reason the authors advance for our problems that I thought was particularly well stated: what they call the “basic research/brute force” bias. The ‘basic research–brute force’ bias is the tendency to overestimate the a… Read More